The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

Panelists discuss exciting phase 3 trial data on a novel selective phosphodiesterase inhibitor that elevates intracellular ...

Chinese scientists have developed a novel nanotherapy known as biomimetic extracellular vesicle spherical nucleic acids ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

In interstitial lung disease (ILD), quantitative computed tomography (qCT) is effective for prognosticating and for disease monitoring.

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that ...

The University of Texas at Tyler was awarded a $219,000 grant to help fund a professor’s pulmonary fibrosis treatment project ...

A Texas researcher received a $219,000 NIH grant to study the potential of a treatment for radiation-induced pulmonary ...

Clinical trials are an important part of IPF research, says columnist Sam Kirton, but we need people willing to participate in them.

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...